Governor Snyder forms task force to address prescription drug an - WNEM TV 5

Governor Snyder forms task force to address prescription drug and opioid problems in Michigan

Posted: Updated:
LANSING, MI (WNEM) -  State officials are moving to focus on what they call the growing prescription drug and opiod problem in Michigan.

Go. Rick Snyder today announced the creation of a task force to deal with the situation, chaired by Lt. Gov. Brian Calley.  

“Prescription drug and opioid addiction has quadrupled the number of unintentional drug deaths in our state since 1999 and we must come together to reverse this trend before more Michiganders are hurt,” Calley said.

Opioids are powerful pain killers that are highly addictive. Opioid dependence affects millions of people in the United States and prescribed opioids can lead to the use of highly addictive and dangerous illegal substances, especially heroin.

The Michigan Prescription Drug and Opioid Abuse Task Force is a result of the call for a comprehensive plan to address prescription drug and opioid abuse in Gov. Snyder's 2015 State of the State address. The bipartisan task force will examine the recent trends, evaluate strategic options, and develop a statewide action plan by fall 2015. The Fiscal Year 2016 budget includes $1.5 million to address statewide concerns on this issue.

Attorney General Bill Schuette and Michigan Department of Health and Human Services Director Nick Lyon also will have leadership roles. The remainder of the task force will include other stakeholders from state government as well as medical, law enforcement and court officials.

“The damaging effects of drugs like opioids are hurting our families and communities,” Schuette said. “We must work together to help end this growing epidemic before it hurts public safety and our economic recovery.”

Copyright 2015 WNEM (The Meredith Corporation.)  All Rights Reserved.



Powered by Frankly
WNEM
Powered by WorldNow CNN
All content © 2017, WNEM; Saginaw, MI. (A Meredith Corporation Station) . All Rights Reserved.
For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.